Morningstar

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

Provided by Dow Jones

By Kelly Cloonan 




  Vertex Pharmaceuticals logged higher revenue in its latest quarter as it continues to see strong demand for its cystic fibrosis treatments. 



  The biotechnology company on Monday posted a third quarter profit of $1.08 billion, or $4.20 a share, compared with $1.05 billion, or $4.01 a share, a year earlier. 



  Adjusted earnings per share were $4.80, ahead of estimates of $4.58 a share according to analysts polled by FactSet. 



  Revenue rose 11% to $3.08 billion, topping the $3.06 billion analysts projected. 



  In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe sickle cell disease and acute pain, respectively, also contributed. 



  International revenue rose 4%. 



  For the year, Vertex raised the low end of its revenue outlook to a range of $11.9 billion to $12 billion from a prior view of $11.85 billion to $12 billion. 



  Write to Kelly Cloonan at kelly.cloonan@wsj.com 



  (END) Dow Jones Newswires



  November 03, 2025 16:44 ET (21:44 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center